ENDRA Life Sciences (NDRA) Cash from Operations (2016 - 2025)
ENDRA Life Sciences has reported Cash from Operations over the past 6 years, most recently at 2652726.0 for Q4 2021.
- Quarterly Cash from Operations fell 27.96% to 2652726.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was 11122384.0 through Dec 2021, down 3.5% year-over-year, with the annual reading at 5182558.0 for FY2025, 29.97% up from the prior year.
- Cash from Operations was 2652726.0 for Q4 2021 at ENDRA Life Sciences, up from 2746763.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 236274.0 in Q1 2017 and troughed at 3451665.0 in Q2 2020.
- The 5-year median for Cash from Operations is 2103281.5 (2020), against an average of 2073061.2.
- Year-over-year, Cash from Operations crashed 937.73% in 2018 and then grew 18.9% in 2021.
- A 5-year view of Cash from Operations shows it stood at 1375584.0 in 2017, then tumbled by 38.3% to 1902427.0 in 2018, then fell by 0.27% to 1907515.0 in 2019, then fell by 8.68% to 2073106.0 in 2020, then fell by 27.96% to 2652726.0 in 2021.
- Per Business Quant, the three most recent readings for NDRA's Cash from Operations are 2652726.0 (Q4 2021), 2746763.0 (Q3 2021), and 2799412.0 (Q2 2021).